Effects of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Hormonal Responses to Macronutrient Ingestion

Lund University

Status and phase: Completed; Phase 4

Conditions: Healthy; Type 2 Diabetes

Treatments: Drug: Sitagliptin; Drug: placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00885638

Lund University Diabetes 001

Details and patient eligibility

About

The regulation by DPP-4 inhibition after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).

Full description

Meal ingestion releases gut hormones which stimulate insulin secretion. A most important gut hormone is the incretin hormone glucagon-like peptide-1 (GLP-1). GLP-1 is rapidly degraded and inactivated after its release by the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibition of DPP-4 therefore increases the concentration of active GLP-1 after meal ingestion, which augments insulin secretion. How this process is regulated after ingested of different individual macronutrients is not known. Therefore, this study examines the influence of ingestion of fat, protein, glucose or mixed meal on the concentrations of incretin hormones and insulin secretion with or without concomitant administration of a DPP-4 inhibitor (sitagliptin).

Enrollment: 12 patients

Sex: Male

Ages: 20 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy men
• Age 20-30 years
• BMI 20-30 kg/m2

Exclusion criteria

• Any disease
• Any medication

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

12 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

A placebo tablet is given before ingestion of macronutrients

Treatment:

Drug: placebo

Sitagliptin

Active Comparator group

Description:

Sitagliptin is given before ingestion of macronutrients

Treatment:

Drug: Sitagliptin